Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-25-000170
Filing Date
2025-08-11
Accepted
2025-08-11 16:25:48
Documents
66
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20250630.htm   iXBRL 10-Q 1444925
2 EX-31.1 exhibit311q22025.htm EX-31.1 9895
3 EX-31.2 exhibit312q22025.htm EX-31.2 9915
4 EX-32.1 exhibit321q22025.htm EX-32.1 5553
5 EX-32.2 exhibit322q22025.htm EX-32.2 5682
  Complete submission text file 0001714899-25-000170.txt   6388018

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20250630.xsd EX-101.SCH 42995
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20250630_cal.xml EX-101.CAL 63661
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20250630_def.xml EX-101.DEF 169967
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20250630_lab.xml EX-101.LAB 573301
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20250630_pre.xml EX-101.PRE 386111
69 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20250630_htm.xml XML 813267
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 251202378
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)